AstraZeneca acquires SixPeaks Bio: the advisors
Globally active biopharmaceutical company AstraZeneca has exercised an option to acquire obesity drug startup SixPeaks Bio. In connection with the deal, Lenz & Staehelin represented AstraZeneca, while Walder Wyss advised SixPeaks Bio and its shareholders.
The deal
The transaction set a total consideration of USD 300 million. The reported amount includes an upfront payment of USD 170 million, as well as an additional fixed payment of USD 30 million and USD 100 million based on achievements of certain regulatory milestones.
The Lenz & Staehelin team
Tino Gaberthüel (M&A, pictured above) led the Lenz & Staehelin team on the matter, working alongside and Raphael Fries, Nils Maag (both M&A), Peter Ling (IP), Pascal Hinny, Franziska Stadtherr-Glättli (both tax), Anja Affolter Marino and Julia van Heusden (both rmployment).
The Walder Wyss team
Partners Robert von Rosen (corporate/M&A, pictured left) and Alexander Gutmans (corporate/M&A and venture capital, pictured right) led the Walder Wyss team on the matter, working alongside managing associates Karina Tschon (corporate/M&A and venture capital), and Michelle Bruni (tax), senior associates Christoph Burckhardt (corporate/M&A) and Bojan Momic (corporate/M&A), as well as associates Oerjan Wickart (corporate/M&A) and Lorenzo Petrone (corporate/M&A).
